Mar. 20, 2019 |
|
April. 08, 2024 |
|
jRCTs031180403 |
A phase II trial of induction CDDP plus TS-1 with concurrent radiotherapy followed by surgical resection in patients with pathologically confirmed stage IIIA-N2 squamous-cell non-small cell lung cancer. |
|
PIT-2 |
Suzuki Kenji |
||
Juntendo University Hospital |
||
3-1-3, Hongo, Bunkyo-ku, Tokyo |
||
+81-3-3813-3111 |
||
kjsuzuki@juntendo.ac.jp |
||
Takamochi Kazuya |
||
Juntendo University Hospital |
||
3-1-3, Hongo, Bunkyo-ku, Tokyo |
||
+81-3-3813-3111 |
||
ktakamo@juntendo.ac.jp |
Not Recruiting |
Dec. 01, 2013 |
||
April. 18, 2014 | ||
45 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
no treatment control/standard of care control |
||
single assignment |
||
treatment purpose |
||
(1) Histologically or cytologically proven squamous cel carcinoma of the lung, diagnosed using specimen material |
||
(1) Uncontrollable systemic disease (hyper tension, diabetes mellitus etc.) |
||
20age old over | ||
75age old under | ||
Both |
||
Primary lung cancer |
||
The surgical resection is performed after 3 cycles of induction concurrent chemoradiotherapy with CDDP, TS-1 and RT45Gy (1.8Gy/fra/day, 25fractions). |
||
Mediastinal lymph node metastasis, Squamous cell carcinoma |
||
Induction chemoradiotherapy, Surgery |
||
2-year progression-free survival |
||
- 5-year progression-free survival |
National Cancer Center Hospital East Certified Review Board | |
6-5-1 Kashiwanoha, Kashiwa-shiChiba-ken, 277-8577 Japan, Chiba | |
+81-4-7133-1111 |
|
ncche-irb@east.ncc.go.jp | |
Approval | |
Mar. 14, 2019 |
UMIN000012413 | |
University hospital Medical Information Network |
none |